Literature DB >> 1390233

P53 gene mutations in acute myelogenous leukaemia.

G Hu1, W Zhang, A B Deisseroth.   

Abstract

A polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) assay was used to identify the exons which contained point mutations in the conserved regions (exons 4-8) of the p53 gene in 49 acute myelogenous leukaemia (AML) patients. SSCP analysis in our study was consistent with the results of subsequent direct DNA sequencing in detecting point mutational change in exons 5 and 8 of one AML patient and in exons 7 and 8 of two additional AML patients. The mutations were located at codons 245 and 273, which have been found in many other tumours, and codons 178 and 290, which have not been reported previously. All of the p53 proteins in which we detected point mutations were immunoprecipitated by the p53 monoclonal antibody PAb 240, which has been shown to recognize a mutant conformation of p53 protein. Thus, our results indicate that functional inactivation of the p53 gene by point mutational change might be one of the mechanisms underlying disease progression of AML.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1390233     DOI: 10.1111/j.1365-2141.1992.tb02979.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

2.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.

Authors:  Kensuke Kojima; Marina Konopleva; Ismael J Samudio; Masato Shikami; Maria Cabreira-Hansen; Teresa McQueen; Vivian Ruvolo; Twee Tsao; Zhihong Zeng; Lyubomir T Vassilev; Michael Andreeff
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

Review 3.  Multidrug resistance (MDR) genes in haematological malignancies.

Authors:  K Nooter; P Sonneveld
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 4.  Apoptosis in leukemias: regulation and therapeutic targeting.

Authors:  Ismael Samudio; Marina Konopleva; Bing Carter; Michael Andreeff
Journal:  Cancer Treat Res       Date:  2010

5.  Analysis of the p53 gene mutations in acute myelogenous leukemia: the p53 gene mutations associated with a deletion of chromosome 17.

Authors:  M Kurosawa; M Okabe; Y Kunieda; M Asaka
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

6.  High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia.

Authors:  Ban Xiong Tan; Kian Hoe Khoo; Tit Meng Lim; David Philip Lane
Journal:  Oncotarget       Date:  2014-02-28

7.  Expression of different conformations of p53 in the blast cells of acute myeloblastic leukaemia is related to in vitro growth characteristics.

Authors:  Y M Zhu; D Bradbury; N Russell
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

8.  Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.

Authors:  C M Barton; N R Lemoine
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.